Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologymedical mutual - ohio Eohilia Coverage Prior Auth …
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Eohilia (Budesonide oral suspension) — Coverage Criteria

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for Eohilia (budesonide oral suspension) used to treat eosinophilic esophagitis (EoE) in patients, specifying indications, prescriber requirements, and approval durations for the payer's pharmacy benefit.

    Policy Summary
    Payermedical mutual - ohio
    PolicyEohilia (Budesonide oral suspension) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateN/A
    Last ReviewMar 19, 2026
    Next Review DateMar 19, 2026
    Key ActionObtain prior authorization with prescription by or in consultation with an allergist or gastroenterologist and document at least 8 weeks of prior PPI and topical esophageal steroid therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 weeksmaximum recommended treatment duration
    ≥ 11 yrsminimum patient age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥ 15/HPFdiagnostic biopsy threshold
    8 weeksprior therapy duration required
    12 weeksinitial authorization duration

    Coverage Criteria for Eohilia (budesonide oral suspension)

    Initial therapy (EoE)

    Covered when ALL of the following are met for Eosinophilic Esophagitis (approve for 12 weeks):

    Age: Patient is >= 11 years of age
    Diagnosis of eosinophilic esophagitis confirmed by endoscopic biopsy demonstrating >= 15 intraepithelial eosinophils per high-power field
    Prior therapies: Patient has received at least 8 weeks of BOTH: (i) proton pump inhibitor; AND (ii) topical (esophageal) corticosteroid>= 8 weeks

    Treatment with a proton pump inhibitor currently or at any time in the past counts. Examples of topical therapy include fluticasone propionate swallowed or budesonide inhalation swallowed.

    Dietary management: Either: patient has tried dietary modifications to manage eosinophilic esophagitis OR prescriber has determined patient is not an appropriate candidate for dietary modifications

    Examples include an elemental diet or an elimination diet

    Treatment status: Either: patient is currently receiving a course of Eohilia and additional medication is needed to complete a 12-week course OR patient has not been treated with Eohilia within the previous 6 months OR patient has recurrent worsening dysphagia after discontinuing Eohilia per prescriber

    For patients who started therapy but have not completed 12 weeks, approve remaining weeks so total treatment equals 12 weeks; maximum recommended treatment duration is 12 weeks.

    Prescriber: Medication is prescribed by or in consultation with an allergist or gastroenterologist

    Initial approval requires specialist involvement

    Coverage is not recommended for circumstances that are not explicitly listed in the Recommended Authorization Criteria. This list is not exhaustive and will be updated as new published data become available.

    Use of Eohilia has not been shown to be safe and effective for treatment of EoE for longer than 12 weeks.

    Key Clinical Thresholds and Coding-Related Criteria

    inv-04: Biopsy eosinophil count
    Biopsy eosinophil count>= 15 intraepithelial eosinophils per high-power field
    Specimen sourceEndoscopic esophageal biopsy
    Use in diagnosisRequired to confirm eosinophilic esophagitis for coverage of Eohilia
    inv-05: Prior therapy duration
    Required prior therapy duration>= 8 weeks of BOTH a proton pump inhibitor and a topical (esophageal) corticosteroid
    PPI timingPPI treatment currently or at any time in the past counts toward the requirement
    Topical steroid examples

    Prescriber Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization and Prescriber Requirement

    Prior authorization is recommended for pharmacy benefit coverage. Initial approval requires the medication be prescribed by, or in consultation with, a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted in the policy; if reauthorization is allowed, a documented response to therapy is required for continuation unless otherwise noted.

    • Initial prescription must be by or in consultation with a specialist for the treated condition.
    • Prior authorization recommended for pharmacy benefit coverage.
    • Initial approval durations follow those specified in the policy; reauthorization requires response to therapy when applicable.
    Step Therapy

    Required Prior Therapies

    Patient must have received at least 8 weeks of both a proton pump inhibitor and a topical (esophageal) corticosteroid prior to approval for eosinophilic esophagitis.

    Clinical Background

    Eosinophilic esophagitis (EoE) is an inflammatory condition of the esophagus. Standard approaches to management include topical (esophageal) corticosteroids and proton pump inhibitors (PPIs). Eohilia (budesonide oral suspension) is indicated for treatment of EoE for up to 12 weeks in patients aged ≥ 11 years.

    Definitions and Diagnostic Thresholds

    inv-12: EoE diagnostic biopsy threshold
    Diagnostic thresholdEosinophilic esophagitis diagnosis confirmed by endoscopic biopsy demonstrating at least 15 intraepithelial eosinophils per high-power field
    Confirmation methodEndoscopic esophageal biopsy is required to document eosinophil count
    Role in coverage decisionMeets one of the core criteria for approval of Eohilia for 12 weeks
    Policy Summary
    Payermedical mutual - ohio
    PolicyEohilia (Budesonide oral suspension) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateN/A
    Last ReviewMar 19, 2026
    Next Review DateMar 19, 2026
    Key ActionObtain prior authorization with prescription by or in consultation with an allergist or gastroenterologist and document at least 8 weeks of prior PPI and topical esophageal steroid therapy.
    SourceLink
    On This Page
    Coverage Criteria for Eohilia (budesonide oral suspension)Key Clinical Thresholds and Coding-Related CriteriaPrescriber Requirements, Prior Authorization, and DocumentationClinical BackgroundDefinitions and Diagnostic Thresholds
    Swallowed fluticasone metered dose inhaler or swallowed budesonide inhalation are acceptable formulations
    inv-06: Minimum age
    Minimum patient age>= 11 years
    Approval age contextEohilia indicated for adults and pediatric patients aged 11 years and older for up to 12 weeks
    DocumentationAge must be documented to meet coverage criteria
    • Minimum 8 weeks of a proton pump inhibitor (current or any time in the past counts).
    • Minimum 8 weeks of a topical (esophageal) corticosteroid (e.g., swallowed fluticasone or budesonide).
    Documentation Required

    Documentation Upon Request

    The Company reserves the right to request additional documentation to support medical necessity as part of its coverage determination process. Upon request, providers must make available patient records, test results, and/or credentials of the provider ordering or performing the service.

    • Examples of documentation that may be requested: endoscopic biopsy results showing ≥ 15 intraepithelial eosinophils per high-power field, records of prior therapies and durations, dietary management attempts, provider credentials.
    • Failure to provide requested documentation may result in denial or delay of coverage determination.
    Denial Risk

    General Denial Conditions

    The Company may deny reimbursement when the drug provided or services performed were not medically necessary, were investigational/experimental, or were not within the member's benefit scope. Denial may also occur when a pattern of inappropriate or excessive billing or practice is identified.

    • Not medically necessary
    • Investigational or experimental use
    • Services or drugs outside the member benefit
    • Patterns of inappropriate or excessive billing or practice